What type of study is this?

September 10, 2025

Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D)+bevacizumab (B)+transarterial chemoembolization (TACE) and placebos+TACE: EMERALD-1 post hoc analysis

CRChristoph RoderburgDüsseldorf University Hospital BSBruno SangroGoethe University Frankfurt MBMohamed BouattourTunis University

Key Points

Radiological progression patterns indicate improved outcomes for HCC patients treated with durvalumab and bevacizumab.
The analysis showed a hazard ratio of 0.77 for progression-free survival in patients receiving the combination therapy compared to placebos.
This observational analysis assessed outcomes by radiological progression patterns in patients with embolization-eligible hepatocellular carcinoma.
These findings may suggest more effective treatment regimens for hepatocellular carcinoma, warranting further investigation.

Abstract

Background: EMERALD-1 (NCT03778957) met its primary endpoint, demonstrating improved PFS in pts with locoregional HCC treated with D+B+TACE vs. placebos (PBO)+TACE (stratified Cox proportional hazards hazard ratio HR, 0.77; 95% confidence interval CI, 0.61–0.98. This post hoc analysis assessed outcomes by radiological progression pattern (radPP) in pts treated with D+B+TACE or PBO+TACE.

AIに質問

Bookmark

View Full Paper